THE CHROMOSOME | Clinical Content Series
Hirsutism Related Hormonal Disorders
Back to Case Studies ArchiveCase Study
She was 31 years old and had been removing facial hair since she was seventeen. Not occasionally, daily. Every morning before leaving her house she spent twenty to thirty minutes managing the hair growth along her jawline, upper lip, chin, and the sides of her face that had been present since adolescence and had worsened progressively across her twenties. She had tried every available hair removal method. She had been to a dermatologist who had offered laser treatment. She had tried the laser. It had reduced the hair temporarily and incompletely, and within months of stopping the treatment sessions the hair had returned with the same density it had carried before. She had concluded, with a resignation that had taken years to settle into acceptance, that this was simply the way her body was and that management rather than resolution was the most she could hope for.
She had also gained 19 kilograms across six years. She had irregular periods, sometimes arriving every five to six weeks, occasionally skipping two months entirely. She had acne along her jawline and chin that had persisted from adolescence into her thirties in a pattern that her dermatologist had attributed to adult hormonal acne without investigating the hormonal origin of the acne beyond prescribing topical and oral treatments that managed the skin without touching the biology producing it. She was tired. She was frustrated. And she had, in the way of Pakistani women who have learned that the medical system will address the surface of their symptoms without ever reaching their origin, largely stopped expecting anything different from the physicians she consulted.
When she came to me she came not with hope but with curiosity, a colleague had told her I asked questions that other doctors did not ask. The first question I asked, after taking her history, was one that no physician had apparently asked before. Not what was growing on her face. But why.
Hirsutism, the growth of terminal hair in a male pattern distribution in women, is not a dermatological condition. It is a hormonal signal. It is the skin's visible expression of androgen excess, of testosterone and its more potent derivative dihydrotestosterone acting on androgen sensitive hair follicles in locations where women's follicles are not designed to respond to androgens with terminal hair growth. The face, the chin, the jawline, the upper lip, the chest, the abdomen, the inner thighs, these are androgen sensitive locations whose follicles produce terminal hair only when androgen levels at the follicle receptor level are excessive. And the key word is at the follicle receptor level, because androgen excess at the follicle does not require abnormal total testosterone on a blood test. It requires either elevated free testosterone, driven by low SHBG, or heightened follicle androgen receptor sensitivity, driven by genetic predisposition, or both simultaneously.
Her total testosterone was within the normal female range. Every physician who had measured it had therefore concluded that her androgen levels were normal and her hirsutism was idiopathic, a word that means we do not know the cause, dressed up in Latin to sound like a diagnosis. Her SHBG was 14 nanomoles per litre, less than half the minimum of the normal female range. Her free testosterone, calculated from the combination of her normal total and her severely suppressed SHBG, was more than twice the upper limit of normal. Her fasting insulin was significantly elevated, the primary driver of her SHBG suppression and a direct stimulant of ovarian androgen production through its effects on ovarian theca cells. Her LH to FSH ratio was disrupted. Her prolactin was mildly elevated, adding an additional androgenic stimulus through its effects on adrenal androgen production. Her cortisol pattern showed significant adrenal activation, contributing adrenal androgens, particularly DHEA and androstenedione, to the total androgenic load acting on her follicles.
This was not idiopathic hirsutism. This was the entirely predictable dermatological consequence of a precise and identifiable hormonal profile, one in which insulin driven SHBG suppression was amplifying the biological activity of a normal total testosterone to the point of clinical androgen excess, while simultaneously driving ovarian androgen overproduction and adrenal androgenic activation that added to the total follicular androgen load. The laser treatment had addressed the hair. It had not addressed the hormone producing it, which was why the hair had returned.
The FTO gene's relationship with hirsutism in Pakistani women is one of the most directly experienced and most consistently undertreated aspects of Pakistani female hormonal medicine. The FTO associated predisposition to hyperinsulinaemia drives the SHBG suppression and ovarian androgen overproduction that produce androgen excess at normal total testosterone levels, creating clinical hirsutism in Pakistani women who are told their testosterone is normal and their hair growth is unexplained. The FTO associated predisposition to visceral fat accumulation amplifies this androgenic environment through peripheral androgen production in adipose tissue and through the inflammatory suppression of SHBG that visceral fat generates independently of insulin. Pakistani women with the FTO associated metabolic profile develop hirsutism earlier, more severely, and at lower total testosterone levels than Western women at equivalent metabolic burden, because the SHBG suppression and follicular androgen amplification that the FTO metabolic profile produces creates androgen excess in the biological environment where hair follicles live regardless of what the blood test measures in the total circulating pool.
We did not recommend further laser treatment as the primary intervention. We treated the hormonal environment producing the hair. We addressed her insulin resistance, the master driver of her SHBG suppression and ovarian androgen overproduction. We restored her SHBG through insulin resistance treatment, visceral fat reduction, and thyroid optimisation. We recalibrated her cortisol, reducing the adrenal androgenic contribution. We addressed her prolactin elevation. We treated her oestrogen progesterone balance, restoring the hormonal counterbalance to androgen activity that adequate progesterone provides.
Fourteen months later her fasting insulin had normalised. Her SHBG had risen to 29 nanomoles per litre, approaching the lower limit of the normal range. Her free testosterone had fallen to within the normal female range for the first time since adolescence. Her facial hair growth had reduced substantially, not eliminated, because the follicles that had been producing terminal hair for fourteen years had established themselves, but growing more slowly, more finely, and requiring management every three to four days rather than every morning. Her acne had resolved completely. Her periods had regularised to a twenty eight to thirty day cycle. She had lost 16 kilograms.
She had not had idiopathic hirsutism. She had had precisely identified, precisely driven hormonal androgen excess that fourteen years of surface management had never touched because nobody had looked at what was producing it. The hormone had always been the answer. The hair had always been the question.
FAQs
Hirsutism is the growth of coarse terminal hair in a male pattern distribution in women, affecting the face, chin, jawline, upper lip, chest, abdomen, and inner thighs in locations where women's hair follicles respond to androgens with terminal hair production. It is classified and treated as a dermatological condition in Pakistani clinical practice, managed with laser, waxing, threading, and topical or oral hair reduction medications, without investigation of the androgenic hormonal environment producing it. This approach treats the symptom while the hormone driving it continues unchecked, which is why hirsutism managed dermatologically without hormonal assessment invariably recurs. Hirsutism is a hormonal signal from the skin, the follicle's visible response to androgen excess at the receptor level, and its resolution requires treating the androgen excess, not the hair it produces.
Hirsutism in Pakistani women with normal total testosterone is almost always driven by one of two mechanisms, or both simultaneously. The first is severely suppressed SHBG, which amplifies the free, biologically active fraction of a normal total testosterone to the point of clinical androgen excess at the follicle level. The second is heightened androgen receptor sensitivity at the hair follicle, a genetic predisposition to follicular androgen responsiveness that produces hirsutism at androgen levels that would not produce terminal hair in less sensitive follicles. In Pakistani women, the FTO associated predisposition to hyperinsulinaemia drives SHBG suppression, creating the first mechanism routinely. The combination of insulin driven SHBG suppression and genetic follicular androgen sensitivity creates the clinical picture of significant hirsutism with normal total testosterone that Pakistani dermatologists classify as idiopathic and Pakistani endocrinologists dismiss because the testosterone is normal. Neither has measured the SHBG.
The FTO gene at Chromosome 16q12.2 drives hirsutism in Pakistani women through its promotion of hyperinsulinaemia, the primary suppressor of hepatic SHBG production and the primary driver of ovarian theca cell androgen overproduction. In Pakistani women with the FTO associated metabolic profile, insulin levels sufficient to produce significant SHBG suppression and ovarian androgen excess develop at lower degrees of overall obesity and at younger ages than in Western women at equivalent metabolic burden. This means that Pakistani women develop the SHBG mediated androgen amplification driving hirsutism earlier in life, frequently in adolescence, and experience its progression through the reproductive years with an acceleration that reflects the worsening hyperinsulinaemia of progressive FTO associated metabolic deterioration. The FTO gene does not produce hirsutism directly, it produces the insulin environment that produces the SHBG suppression that produces the androgen excess that the follicle then expresses as hair.
Insulin drives androgen excess in Pakistani women through two simultaneous pathways that compound each other. First, elevated insulin acts directly on ovarian theca cells, the cells responsible for testosterone production, through insulin receptors that respond to hyperinsulinaemia by increasing androgen synthesis. The ovary, in the presence of high insulin, overproduces testosterone independently of LH stimulation, creating an ovarian androgen excess that is entirely driven by the metabolic environment rather than by a primary reproductive hormone abnormality. Second, elevated insulin directly suppresses hepatic SHBG production, reducing the binding protein that would otherwise contain the biological activity of the excess testosterone being produced. The combination of increased androgen production and decreased androgen binding produces the clinical androgen excess that drives hirsutism, acne, and menstrual irregularity, and it does so at total testosterone levels that may remain entirely within the normal female reference range.
The adrenal glands produce androgens, primarily DHEA, DHEA-S, and androstenedione, that contribute to the total androgenic load acting on hair follicles independently of ovarian testosterone production. In Pakistani women with cortisol dysregulation and adrenal activation, driven by chronic stress, sleep disruption, and the hypothalamic pituitary adrenal axis sensitisation of the FTO associated metabolic profile, adrenal androgen production is elevated beyond its normal baseline. This adrenal androgenic contribution adds to the ovarian androgen excess driven by hyperinsulinaemia, compounding the total follicular androgen load and worsening the hirsutism that ovarian androgens alone would produce. Pakistani women under sustained psychological and physiological stress carry an adrenal androgenic burden that is a clinically significant and almost entirely overlooked driver of hirsutism severity, and it resolves when cortisol is treated rather than when the hair is removed.
Laser hair removal destroys hair follicles that are actively producing hair at the time of treatment, reducing hair density in the treated area through follicle destruction. It does not address the androgenic hormonal environment that continues to stimulate the androgen sensitive follicles that survive the laser treatment and the follicles in adjacent areas that have not yet been activated to terminal hair production by the ongoing androgen excess. In Pakistani women with untreated hormonal androgen excess, laser treatment provides temporary reduction, the destroyed follicles do not regrow, but the surviving and newly activated follicles continue responding to the unchanged androgenic environment with ongoing terminal hair production that restores clinical hirsutism over months to years. Treating the hormonal driver of hirsutism before or alongside laser treatment produces both more complete initial response, because reducing androgen levels at the follicle level reduces the density and activity of the hair being treated, and more sustained long term outcome, because the androgenic stimulus driving follicle activation is removed.
The psychological burden of hirsutism in Pakistani women is substantially greater than its physical significance, because Pakistani cultural standards of female appearance, the social visibility of facial hair, and the cultural stigma attached to perceived masculinisation of female appearance create a level of psychological distress that daily hair management both reflects and sustains. Pakistani women with hirsutism spend significant time, money, and emotional energy managing a symptom that is never resolved because its hormonal origin is never treated, living in a daily relationship with their appearance that is defined by concealment and management rather than by resolution and freedom. The shame associated with hirsutism in Pakistani culture produces delays in help seeking, underreporting of symptoms, and a pattern of dermatological consultation that addresses the hair without the hormonal investigation that would identify and treat its origin. THE CHROMOSOME protocol treats hirsutism as a hormonal disorder with significant psychological consequences, addressing both the biology producing the hair and the psychological impact that years of unaddressed hormonal disorder have produced.
The degree of hirsutism reversal achievable with hormonal treatment in Pakistani women depends critically on the duration of the androgenic stimulus and the degree of follicle terminal differentiation that has occurred. Hair follicles that have recently been activated to terminal hair production by androgen excess are more responsive to hormonal reversal, reducing back to vellus hair growth when the androgenic stimulus is removed. Follicles that have produced terminal hair for many years are more permanently differentiated and less likely to fully revert, meaning that the hair reduction achievable through hormonal treatment alone is significant but may not be complete in patients with long standing hirsutism. In Dr. Zaar's clinical experience, comprehensive hormonal treatment of the underlying androgen excess produces substantial and clinically meaningful hirsutism reduction in Pakistani women, slower growth, finer texture, reduced density, and less frequent management requirement, with the degree of reduction proportional to the completeness of androgenic normalisation achieved and the duration of androgenic exposure preceding treatment. The combination of hormonal normalisation and targeted cosmetic intervention, applied once the hormonal environment has been optimised, produces the most complete and most durable outcome available to Pakistani women with hormonally driven hirsutism.